Cover Image
市場調查報告書

ACO:對製藥公司帶來的影響

Accountable Care Organizations: What Impact on Pharma?

出版商 Datamonitor Healthcare 商品編碼 342058
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
ACO:對製藥公司帶來的影響 Accountable Care Organizations: What Impact on Pharma?
出版日期: 2015年07月16日 內容資訊: 英文 50 Pages
簡介

ACO (Accountable Care Organization:對患者具有責任的治療組織) 是美國新醫療保健系統實體。

本報告提供ACO現況相關驗證,提供各種ACO,及醫療·製藥形勢的影響等系統性資訊。

摘要整理

合適的照護,有責任的照護:製藥公司照護為何?

  • 付款改革:重值不重量
  • 製藥公司的ACO問題成熟化·擴大
  • 根據價值的照護之主要的條件與企業
  • 參考文獻

ACO千差萬別

  • ACO在結構,規模,文化,風險方面的不同
  • 改變ACO主題之要素
  • 變化·合併的提供者情勢上之勝者和敗者
  • 醫生主導的ACO
  • 參考文獻

ACO,製藥公司,投藥管理

  • 大部分ACO都不列入服藥管理上的優先順序
  • 醫療保險中部分ACO使用更多的藥
  • 民間ACO注目於短期性降低成本
  • 醫生角色和獎勵的變化
  • ACO是否與製藥公司定有契約?
  • 藥劑師是否為新的醫生?
  • 對藥劑師的阻礙因素
  • 製藥公司用其他方法幫助ACO:資料,教育,患者支援
  • 參考文獻

ACO至今的結果

  • 降低成本
  • 案例研究分析:ACO的成功案例
  • 參考文獻

附錄

圖表

目錄
Product Code: DMKC0141953

The Affordable Care Act (ACA) passed in 2010 was the catalyst to a range of changes to the US healthcare system. Among the most important of these changes was how healthcare is paid for, with a number of ACA measures aimed at moving away from a fee-for-service reimbursement to payment of providers according to outcomes and quality of care. This shift from volume- to value-based reimbursement is captured most prominently in the establishment of Accountable Care Organizations (ACOs). ACOs are groups of doctors, hospitals, and other healthcare providers that share the risk, responsibility, and reward associated with delivering more cost-effective, higher-quality, and better-coordinated care. There are now over 700 ACOs in the US, spanning both the publicly funded Medicare and Medicaid, as well as the private sector.

The impact of this growing ACO movement on the pharma industry has so far been limited, but this is changing. Pharma firms have opportunities to engage with these restructured providers in new ways, including by helping to influence and set treatment best practice across different therapy areas, providing pharmacoeconomic and outcomes data, and potentially supporting a more prominent role for pharmacists within ACOs.

This report addresses the following questions:

  • What are ACOs and how do they differ from other players in the US healthcare system?
  • How is the role of medication management evolving within ACOs?
  • What impact have ACOs had on the pharmaceutical market so far and how will that change in the future?
  • What strategies for pharma-ACO engagement will be most successful?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • 1. Affordable care, accountable care: should pharma care?
  • 2. ACOs come in many shapes and sizes
  • 3. ACOs, pharma, and medication management
  • 4. ACO results so far

AFFORDABLE CARE, ACCOUNTABLE CARE: SHOULD PHARMA CARE?

  • 5. Payment reform: from volume to value
  • 6. Maturing, multiplying ACOs matter to pharma
  • 7. Key terms and players in value-based care
  • 8. Bibliography

ACOS COME IN MANY SHAPES AND SIZES

  • 9. ACOs vary in structure, size, culture, and risk
  • 10. Variations on the ACO theme
  • 11. Winners and losers in a shifting, consolidating provider landscape
  • 12. Physician-led ACOs considered best for care, with health plan support
  • 13. Bibliography

ACOS, PHARMA, AND MEDICATION MANAGEMENT

  • 14. Medication management is not a priority for most ACOs
  • 15. Some Medicare ACOs may be using more drugs
  • 16. Commercial ACOs' focus on short-term savings means drug cost caps
  • 17. Changing roles and incentives for physicians
  • 18. More formulary power to providers
  • 19. ACO-pharma contracting? Not yet, but soon
  • 20. Pharmacists as the new physicians?
  • 21. Barriers to promoting pharmacists, 22.Pharma can help ACOs in other ways: data, education, and patient support
  • 23. Bibliography

ACO RESULTS SO FAR

  • 24. Savings are modest
  • 25. Case study analysis: ACO success stories
  • 26. Bibliography

APPENDIX

  • 27. About the author
  • 28. Scope
  • 29. Methodology
Back to Top